
SIF DOCUMENTS ON
DRUGS FOR COVID-19 COVID-19
SIF Documents on drugs for COVID-19
From this page you can download documentation produced by the Italian Society of Pharmacology relating to drugs and therapies used to treat patients with COVID-19.
We also suggest consulting the page LINKS TO COVID-19 WEB RESOURCES, where there are updates on the COVID-19 pandemic and the page LINKS TO PUBLISHED PAPERS ON COVID-19 where scientific publications are listed that report and discuss the drugs and pharmacological treatments of patients with COVID-19.
-
22 novembre 2021
Molnupiravir – Scheda informativa per il trattamento della CoViD-19
A cura di: Gloria Ravegnini, Gianni Sava.
-
22 aprile 2021
Eventi avversi dei vaccini anti-SARS-CoV-2 di Pfizer-BioNTech, Moderna, AstraZeneca e J&J
A cura di: Giuseppe Nocentini, Luigi Cari, Gianni Sava, Giorgio Racagni - 22 aprile 2021
-
22 aprile 2021
Note sull’efficacia dei 4 vaccini anti-CoViD-19 attualmente in uso
A cura di: Giuseppe Nocentini, Luigi Cari, Gianni Sava, Giorgio Racagni
-
26 marzo 2021
Eventi avversi dei vaccini anti-SARS-CoV-2 di Pfizer-Biontech, Moderna e AstraZeneca
A cura di Giuseppe Nocentini e Gianni Sava, Società Italiana di Farmacologia - 26 marzo 2021
-
22 febbraio 2021
Information sheet Intravenous tocilizumab for the treatment of patients with severe COVID-19 infection
Update March 16, 2021 - Edited by: Gianluca Trifirò, Valentina. Isgrò, Silvia Arena (University of Messina), Filippo Drago and Lucia Gozzo (University of Catania)
-
16 ottobre 2020
Chloroquine/hydroxychloroquine to prevent and treat COVID-19
Edited by: Gianluca Trifirò, Salvatore Crisafulli – University of Messina and Andrea Cignarella – University of Padova. October 16, 2020 update by Gianluca Trifirò, Salvatore Crisafulli, Andrea Cignarella
-
1 luglio 2020
IUPHAR response to COVID-19
-
27 aprile 2020
Information Data Sheet Remdesivir for intravenous use for the treatment of patients with COVID-19 (SARS-CoV-2) syndrome
Edited by: Antonio D’Avolio, Associate Professor of Pharmacology, University of Turin, and Valeria Avataneo, PhD, University of Turin.
-
10 aprile 2020
DARUNAVIR/COBICISTAT
Edited by Annalisa Capuano, Società Italiana di Farmacologia, SIF Crisis Unit on SARS-CoV-2, Alessia Zinzi, University of Campania “Luigi Vanvitelli”
-
8 aprile 2020
ANAKINRA
Edited by Annalisa Capuano, Società Italiana di Farmacologia, SIF Crisis Unit on SARS-CoV-2, Carmen Ferrajolo, Gabriella di Mauro, University of Campania “Luigi Vanvitelli”
-
8 aprile 2020
EMAPALUMAB
Edited by: Annalisa Capuano, SIF Crisis Unit on SARS-CoV-2, Carmen Ferrajolo and Mario Gaio, University of Campania “Luigi Vanvitelli”
-
7 aprile 2020
SARILUMAB
Edited by: Annalisa Capuano, SIF Crisis Unit on SARS-CoV- 2, Carmen Ferrajolo and Federica Fraenza, University of Campania “Luigi Vanvitelli”
-
7 aprile 2020
COVID-19 hazard in patients with rare diseases. What drugs to take with caution?
Edited by Sabata Pierno and Annamaria De Luca – SIF Crisis Unit on SARS-CoV-2 and University of Bari
-
6 aprile 2020
Safe use of sanitizers against SARS-CoV-2
Edited by Valerio Ciccone, Shirley Genah and Marina Ziche SIF Crisis Unit on SARS-CoV-2 and University of Siena
-
27 marzo 2020
FAVIPIRAVIR
Edited by: Annalisa Capuano, SIF Crisis Unit on SARS-CoV-2, Carmen Ferrajolo, University of Campania “Luigi Vanvitelli”
-
20 marzo 2020
Non-steroidal anti-inflammatory drugs (NSAIDs) and the increased risk of complications during infections. A literature review
Edited by the Section of Clinical Pharmacology of the Italian Society of Pharmacology
-
13 marzo 2020
Official statement of the Italian Society of Pharmacology on the use of ACE-inhibitors or angiotensin receptor blockers in COVID-19 infection
Edited by Prof. Gianluca Trifirò, by the Section of Clinical Pharmacology of the Italian Society of Pharmacology (SIF) and by the Cardiovascular and Metabolic Working Groups of SIF
DISCLAIMER
The contents of this site are intended for purely informational purposes.
The Italian Society of Pharmacology (SIF) does not accept any responsibility for possible errors, forgetfulness, or bad interpretations present in these pages or in those referred to (link).